Drug profile · INN
atazanavir
REYATAZ
atazanavir (REYATAZ) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
EMA: approved TGA: approved Antiinfectives for systemic use (J05) J05AE08
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — atazanavir
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
atazanavir (REYATAZ) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
Key facts
INN atazanavir
Brand REYATAZ
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AE08
Originator Bristol-Myers Squibb Australia Pty Ltd
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is atazanavir?
atazanavir (REYATAZ) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd.
What is the brand name for atazanavir?
REYATAZ is a marketed brand name for atazanavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.